Maravai Lifesciences Holdings (MRVI) Long-Term Deferred Tax (2020 - 2023)

Maravai Lifesciences Holdings' Long-Term Deferred Tax history runs 4 years deep, the most recent figure standing at $773.7 million for Q3 2023.

• On a quarterly basis, Long-Term Deferred Tax changed 0.33% year-over-year to $773.7 million in Q3 2023; TTM through Sep 2023 was $773.7 million, a 0.33% change from a year earlier, with the FY2022 full-year figure at $765.8 million, down 5.24% from the prior year.
• Long-Term Deferred Tax grew to $773.7 million in Q3 2023 per MRVI's latest filing, from $769.6 million in the prior quarter.
• Across five years, Long-Term Deferred Tax topped out at $820.8 million in Q3 2021 and bottomed at $419.9 million in Q1 2021.
• The 4-year median for Long-Term Deferred Tax is $770.4 million (2022), against an average of $705.9 million.
• Biggest YoY gain for Long-Term Deferred Tax was 88.9% in 2022; the steepest drop was 6.05% in 2022.
• Year by year, Long-Term Deferred Tax stood at $431.7 million in 2020, then jumped by 87.19% to $808.1 million in 2021, then decreased by 5.24% to $765.8 million in 2022, then grew by 1.03% to $773.7 million in 2023.
• Per Business Quant, the three latest MRVI Long-Term Deferred Tax figures stand at $773.7 million (Q3 2023), $769.6 million (Q2 2023), and $767.0 million (Q1 2023).